pre-IPO PHARMA

verve-therapeutics PRESS RELEASE ARCHIVE

Jun 16, 2021

Verve Therapeutics Announces Pricing of Initial Public Offering


Jun 1, 2021

Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors


Jun 1, 2021

Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease


May 19, 2021

Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates


May 11, 2021

Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT



May 5, 2021

Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors


Mar 12, 2021

Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease


Jan 19, 2021

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease


Jan 19, 2021

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease


Jan 12, 2021

Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates



Jan 6, 2021

Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference


Nov 23, 2020

Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference


Nov 9, 2020

Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020


Sep 25, 2020

Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit


Aug 13, 2020

Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series



Aug 13, 2020

Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series


Jun 27, 2020

Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting


Jun 27, 2020

Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting


Jun 17, 2020

Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting


Jun 17, 2020

Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting



Jun 17, 2020


Jun 11, 2020

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease


Jun 11, 2020

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease


Jan 1, 2020

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease


Oct 3, 2019

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer



Oct 3, 2019

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer


Oct 2, 2019

Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit


Oct 2, 2019

Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit


Sep 16, 2019

Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board


Sep 16, 2019

Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board



May 7, 2019

Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV


May 7, 2019

Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV


Google Analytics Alternative